PubMed Health⌕ Search

PubMed · 12083934

Long-range electron transfer across molecule-nanocrystalline semiconductor interfaces using tripodal sensitizers.

Abstract

Four tripodal sensitizers, Ru(bpy)(2)(Ad-tripod-phen)(2+) (1), Ru(bpy)(2)(Ad-tripod-bpy)(2+) (2), Ru(bpy)(2)(C-tripod-phen)(2+) (3), and Ru(bpy)(2)(C-tripod-bpy)(2+) (4) (where bpy is 2,2'-bipyridine, phen is 1,10-phenanthroline, and Ad-tripod-bpy (phen) and C-tripod-bpy (phen) are tripod-shaped bpy (phen) ligands based on 1,3,5,7-tetraphenyladamantane and tetraphenylmethane, respectively), have been synthesized and characterized. The tripodal sensitizers consist of a rigid-rod arm linked to a Ru(II)-polypyridine complex at one end and three COOR groups on the other end that bind to metal oxide nanoparticle surfaces. The excited-state and redox properties of solvated and surface-bound 1-4 have been studied at room temperature. The absorption spectra, emission spectra, and electrochemical properties of 1-4 in acetonitrile solution are preserved when 1-4 are bound to nanocrystalline (anatase) TiO(2) or colloidal ZrO(2) mesoporous films. This behavior is indicative of weak electronic coupling between TiO(2) and the sensitizer. The kinetics for excited-state decay are exponential for 1-4 in solution and are nonexponential when 1-4 are bound to ZrO(2) or TiO(2). Efficient and rapid (k(cs) > 10(8) s(-)(1)) excited-state electron injection is observed for 1-4/TiO(2). The recombination of the injected electron with the oxidized Ru(III) center is well described by a second-order kinetic model with rate constants that are independent of the sensitizer. The sensitizers bound to TiO(2) were reversibly oxidized electrochemically with an apparent diffusion coefficient approximately 1 x 10(-11) cm(2) s(-)(1).

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Elena Galoppini, Wenzhuo Guo, Wei Zhang, Paul G Hoertz, Ping Qu, Gerald J Meyer. 2002-07-03. Long-range electron transfer across molecule-nanocrystalline semiconductor interfaces using tripodal sensitizers.. https://doi.org/10.1021/ja025840n

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗